Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 13/05/2024
• Auteurs : Anna-Lena NeehusBrenna CareyMarija LandekicPatricia PanikulamGail DeutschMasato OgishiCarlos A. Arango-FrancoQuentin PhilippotMohammadreza ModaresiIraj MohammadzadehMelissa Corcini BerndtDarawan RinchaiTom Le VoyerJérémie RosainMana MomenilandiMarta MartinTaushif KhanJonathan BohlenJi Eun HanAlexandre DeslysMathilde BernardTania Gajardo-CarrascoCamille SoudéeCorentin Le Floc’hMélanie MigaudYoann SeeleuthnerMi-Sun JangEirini NikolouliSimin SeyedpourHugues BegueretJean-François EmilePierre Le GuenGuido TavazziCostanza Natalia Julia ColomboFederico Capra MarzaniMicol AngeliniFrancesca TrespidiStefano GhirardelloNasrin Alipour OlyaeiAnne MolitorRaphaël CarapitoMohsen MazloomrezaeiHassan Rokni-ZadehMajid Changi-AshtianiChantal BrouzesPablo VargasAlessandro BorghesiNico LachmannSeiamak BahramBruno CrestaniMichael FayonFrançois GalodeSusanta PahariLarry S. SchlesingerNico MarrDusan BogunovicStéphanie Boisson-DupuisVivien BéziatLaurent AbelRaphael BorieLisa R. YoungRobin DeterdingMohammad ShahrooeiNima RezaeiNima ParvanehDaniel CravenPhilippe GrosDanielle MaloFernando E. SepulvedaLawrence M. NogeeNathalie AladjidiBruce C. TrapnellJean-Laurent CasanovaJacinta Bustamante
• Organismes : Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Institut Necker Enfants-Malades Hôpital Necker - Enfants Malades [AP-HP] Institut Necker Enfants-Malades Hôpital Necker - Enfants Malades [AP-HP] Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Institut Necker Enfants-Malades Hôpital Necker - Enfants Malades [AP-HP] Institut Necker Enfants-Malades Hôpital Necker - Enfants Malades [AP-HP] Institut Necker Enfants-Malades Hôpital Necker - Enfants Malades [AP-HP] Institut Necker Enfants-Malades Hôpital Haut-Lévêque [CHU Bordeaux] Hôpital Ambroise Paré [AP-HP] Physiopathologie et Epidémiologie des Maladies Respiratoires AP-HP - Hôpital Bichat - Claude Bernard [Paris] Immuno-Rhumatologie Moléculaire Fédération Hospitalo-Universitaire Fédération de Médecine Translationnelle de Strasbourg Centre de Recherche en Biomédecine de Strasbourg Immuno-Rhumatologie Moléculaire Fédération Hospitalo-Universitaire Fédération de Médecine Translationnelle de Strasbourg Centre de Recherche en Biomédecine de Strasbourg Immuno-Rhumatologie Moléculaire Fédération Hospitalo-Universitaire Fédération de Médecine Translationnelle de Strasbourg Centre de Recherche en Biomédecine de Strasbourg Nouvel Hôpital Civil de Strasbourg Hôpital Necker - Enfants Malades [AP-HP] Immuno-Rhumatologie Moléculaire Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] Centre Hospitalier Universitaire de Bordeaux Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] Centre Hospitalier Universitaire de Bordeaux Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Rockefeller University [New York] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Rockefeller University [New York] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Rockefeller University [New York] Hôpital Necker - Enfants Malades [AP-HP] Imagine - Institut des maladies génétiques (IHU) CIC Bordeaux Centre Hospitalier Universitaire de Bordeaux Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Rockefeller University [New York] Howard Hughes Medical Institute [New York] Imagine - Institut des maladies génétiques (IHU) Hôpital Necker - Enfants Malades [AP-HP] Rockefeller University [New York]
• Publié dans Cell le 28/10/2020

---

Résumé : We describe a human lung disease caused by autosomal recessive, complete deficiency of the monocyte chemokine receptor C-C motif chemokine receptor 2 (CCR2). Nine children from five independent kindreds have pulmonary alveolar proteinosis (PAP), progressive polycystic lung disease, and recurrent infections, including bacillus Calmette Guérin (BCG) disease. The CCR2 variants are homozygous in six patients and compound heterozygous in three, and all are loss-of-expression and loss-of-function. They abolish CCR2-agonist chemokine C-C motif ligand 2 (CCL-2)-stimulated Ca2+ signaling in and migration of monocytic cells. All patients have high blood CCL-2 levels, providing a diagnostic test for screening children with unexplained lung or mycobacterial disease. Blood myeloid and lymphoid subsets and interferon (IFN)-γ- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-mediated immunity are unaffected. CCR2-deficient monocytes and alveolar macrophage-like cells have normal gene expression profiles and functions. By contrast, alveolar macrophage counts are about half. Human complete CCR2 deficiency is a genetic etiology of PAP, polycystic lung disease, and recurrent infections caused by impaired CCL2-dependent monocyte migration to the lungs and infected tissues.

---

Fichiers liés : islandora_171852.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/05/2024
• Auteurs : Wigneron J.-P.Philippe CiaisXiaojun LiMartin BrandtJosep G CanadellFeng TianHuan WangAna BastosLei FanGabriel GaticaRahul KashyapXiangzhuo LiuStephen SitchShengli TaoXiangming XiaoHui YangJ.C. EspinozaFrédéric FrappartWei LiYuanwei QinAurélien de TruchisRasmus Fensholt
• Organismes : Interactions Sol Plante Atmosphère Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Interactions Sol Plante Atmosphère IT University of Copenhagen CSIRO Environment Business Unit Wuhan University [China] Peking University [Beijing] Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München Southwest University [Chongqing] Consejo Nacional de Investigaciones Científicas y Técnicas [Buenos Aires] Indian Institute of Technology Kharagpur Interactions Sol Plante Atmosphère University of Exeter Peking University [Beijing] University of Oklahoma Max Planck Institute for Biogeochemistry Institut des Géosciences de l’Environnement Interactions Sol Plante Atmosphère Qing hua da xue = Tsinghua University = Université Tsinghoua [Beijing] University of Oklahoma Kayrros IT University of Copenhagen
• Publié dans Frontiers in Remote Sensing le 16/08/2021

---

Résumé : Monitoring forest carbon (C) stocks is essential to better assess their role in the global carbon balance, and to better model and predict long-term trends and inter-annual variability in atmospheric CO2 concentrations. On a national scale, national forest inventories (NFIs) can provide estimates of forest carbon stocks, but these estimates are only available in certain countries, are limited by time lags due to periodic revisits, and cannot provide spatially continuous mapping of forests. In this context, remote sensing offers many advantages for monitoring above-ground biomass (AGB) on a global scale with good spatial (50–100 m) and temporal (annual) resolutions. Remote sensing has been used for several decades to monitor vegetation. However, traditional methods of monitoring AGB using optical or microwave sensors are affected by saturation effects for moderately or densely vegetated canopies, limiting their performance. Low-frequency passive microwave remote sensing is less affected by these saturation effects: saturation only occurs at AGB levels of around 400 t/ha at L-band (frequency of around 1.4 GHz). Despite its coarse spatial resolution of the order of 25 km × 25 km, this method based on the L-VOD (vegetation optical depth at L-band) index has recently established itself as an essential approach for monitoring annual variations in forest AGB on a continental scale. Thus, L-VOD has been applied to forest monitoring in many continents and biomes: in the tropics (especially in the Amazon and Congo basins), in boreal regions (Siberia, Canada), in Europe, China, Australia, etc. However, no reference study has yet been published to analyze L-VOD in detail in terms of capabilities, validation and results. This paper fills this gap by presenting the physical principles of L-VOD calculation, analyzing the performance of L-VOD for monitoring AGB and reviewing the main applications of L-VOD for tracking the carbon balance of global vegetation over the last decade (2010–2019).

---

Fichiers liés : frsen-05-1338618.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/05/2024
• Auteurs : Michael CooremanJaved ButlerRobert GiuglianoFaiez ZannadLucile DzenPhilippe Huot-MarchandMartine BaudinDaniel BeardJean-Louis JunienPierre BroquaManal AbdelmalekSven Francque
• Organismes : Research and Development, Inventiva, New York Inventiva [Daix] Baylor Scott & White Research Institute Harvard Medical School [Boston] Brigham and Women's Hospital [Boston] Défaillance Cardiovasculaire Aiguë et Chronique Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] French-Clinical Research Infrastructure Network - F-CRIN [Paris] Research and Development, Inventiva, New York Inventiva [Daix] Research and Development, Inventiva, New York Inventiva [Daix] Research and Development, Inventiva, New York Inventiva [Daix] Translational Medicine Academy Research and Development, Inventiva, New York Inventiva [Daix] Research and Development, Inventiva, New York Inventiva [Daix] Mayo Clinic [Rochester] Antwerp University Hospital [Edegem] Universiteit Antwerpen = University of Antwerp
• Publié dans Nature Communications le 23/10/2020

---

Résumé : Abstract Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE trial secondary and exploratory outcomes (ClinicalTrials.gov NCT03008070) were analyzed for the effect of lanifibranor on IR, lipid and glucose metabolism, systemic inflammation, blood pressure (BP), hepatic steatosis (imaging and histological grading) for all patients of the original analysis. With lanifibranor, triglycerides, HDL-C, apolipoproteins, insulin, HOMA-IR, HbA1c, fasting glucose (FG), hs-CRP, ferritin, diastolic BP and steatosis improved significantly, independent of diabetes status: most patients with prediabetes returned to normal FG levels. Significant adiponectin increases correlated with hepatic and CMH marker improvement; patients had an average weight gain of 2.5 kg, with 49% gaining ≥2.5% weight. Therapeutic benefits were similar regardless of weight change. Here, we show that effects of lanifibranor on liver histology in MASH are accompanied with CMH improvement, indicative of potential cardiovascular clinical benefits.

---

Fichiers liés : s41467-024-47919-9.pdf

---

Source

---

• Type de publi. :
• Date de publi. : 09/05/2024
• Auteurs : Daniela Rodrigues-BrazLinxin ZhuEmmanuelle GélizéJean-Pierre ClarinXavier ChatagnonYoucef BenzinePhilippe RampignonAgathe ThouveninJean-Louis BourgesFrancine Behar-CohenMin Zhao
• Organismes : Centre de Recherche des Cordeliers

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 09/05/2024
• Auteurs : Liudmila ChelyshevaHalima MorinEric BiotAntoine NicolasPhilippe RechMarco da CostaLisa BarelPatrick LaufsJean-Christophe Palauqui
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut des Sciences des Plantes de Paris-Saclay Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Centre National de la Recherche Scientifique AgroParisTech Institut National de la Recherche Agronomique Sorbonne Université Institut Jean-Pierre Bourgin - Sciences du végétal Laboratoire de Biologie du Développement [IBPS] Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans The Plant Journal le 26/10/2020

---

Résumé : Gene expression analysis is essential for understanding the mechanisms involved in plant development. Here, we developed M2WISH, a protocol based on M icro W ave treatment for W holemount mRNA I n S itu H ybridization in Arabidopsis. By permeabilizing tissues without damaging cellular organization this protocol results in high and homogeneous hybridization yields that enable systematic analysis of gene expression dynamics. Moreover, when combined with cellular histochemical staining, M2WISH successfully provides a cellular resolution of gene expression. Thus, we demonstrate the robustness of M2WISH with 10 genes on roots, aerial meristems, leaves, and embryos in the seed. We applied M2WISH to study the spatial dynamics of WUSCHEL ( WUS ) and CLAVATA3 ( CLV3 ) expression during in vitro meristematic conversion of roots into shoot apical meristems. Thus, we showed that shoot apical meristems could arise from two different types of root structures that differed by their CLV3 gene expression patterns. We constructed 3D cellular representations of WUS and CLV3 gene co‐expression pattern and stressed the variability inherent to meristem conversion. Thus, this protocol generates a large amount of data on the localization of gene expression, which can be used to model complex systems.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/05/2024
• Auteurs : Bastien Le GuellecAlexandre LefevreCharlotte GeayLucas ShortenCyril BrugeLotfi Hacein-BeyPhilippe AmouyelJean-Pierre PruvoGregory KuchcinskiAghiles Hamroun
• Organismes : Departement de Neuroradiologie [Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Departement de Neuroradiologie [Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Departement de Neuroradiologie [Lille] University of California [Davis] Centre Hospitalier Régional Universitaire [CHU Lille] Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 Departement de Neuroradiologie [Lille] Plateformes Lilloises en Biologie et Santé - UAR 2014 - US 41 Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Lille Neurosciences & Cognition - U 1172 Departement de Neuroradiologie [Lille] Plateformes Lilloises en Biologie et Santé - UAR 2014 - US 41 Centre Hospitalier Régional Universitaire [CHU Lille] Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167
• Publié dans Radiology: Artificial Intelligence le 23/01/2021

---

Résumé : Purpose To assess the performance of a local open-source large language model (LLM) in various information extraction tasks from real-life emergency brain MRI reports. Materials and Methods All consecutive emergency brain MRI reports written in 2022 from a French quaternary center were retrospectively reviewed. Two radiologists identified MRI scans that were performed in the emergency department for headaches. Four radiologists scored the reports’ conclusions as either normal or abnormal. Abnormalities were labeled as either headache-causing or incidental. Vicuna (LMSYS Org), an open-source LLM, performed the same tasks. Vicuna’s performance metrics were evaluated using the radiologists’ consensus as the reference standard. Results Among the 2398 reports during the study period, radiologists identified 595 that included headaches in the indication (median age of patients, 35 years [IQR, 26–51 years]; 68% [403 of 595] women). A positive finding was reported in 227 of 595 (38%) cases, 136 of which could explain the headache. The LLM had a sensitivity of 98.0% (95% CI: 96.5, 99.0) and specificity of 99.3% (95% CI: 98.8, 99.7) for detecting the presence of headache in the clinical context, a sensitivity of 99.4% (95% CI: 98.3, 99.9) and specificity of 98.6% (95% CI: 92.2, 100.0) for the use of contrast medium injection, a sensitivity of 96.0% (95% CI: 92.5, 98.2) and specificity of 98.9% (95% CI: 97.2, 99.7) for study categorization as either normal or abnormal, and a sensitivity of 88.2% (95% CI: 81.6, 93.1) and specificity of 73% (95% CI: 62, 81) for causal inference between MRI findings and headache. Conclusion An open-source LLM was able to extract information from free-text radiology reports with excellent accuracy without requiring further training.

---

Fichiers liés : le-guellec-et-al-2024-performance-of-an-open-source-large-language-model-in-extracting-information-from-free-text.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/05/2024
• Auteurs : Adil MaaroufJan Patrick StellmannAudrey RicoClemence BoutiereS. DemortièrePierre DurozardW ZaaraouiJean-Philippe RanjevaJean PelletierBertrand Audoin
• Organismes : Hôpital de la Timone [CHU - APHM] Centre de résonance magnétique biologique et médicale Centre de résonance magnétique biologique et médicale Centre de résonance magnétique biologique et médicale Hôpital de la Timone [CHU - APHM] Hôpital de la Timone [CHU - APHM] Hôpital de la Timone [CHU - APHM] Centre de résonance magnétique biologique et médicale Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] Centre de résonance magnétique biologique et médicale Centre de résonance magnétique biologique et médicale Centre de résonance magnétique biologique et médicale
• Publié dans Journal of Neurology, Neurosurgery and Psychiatry le 25/10/2020

---

Résumé : Background: Progression independent of relapse activity (PIRA) has been described since the early stage of relapsing multiple sclerosis (RMS). However, little is known about the relation between PIRA and inflammatory activity that is particularly important at this stage of the disease. Method: We included 110 patients in a prospective study within 18 months of RMS onset. MRI examinations and clinical visits were scheduled on the same day for months 0, 6, 12, 24, 36, 60, 84, 120, 180 and 240. Results: The mean (SD) age of patients was 30 (6.7) years at inclusion and median (range) follow-up 15 (9-20) years. Analysis of 1118 between-visit intervals revealed 93 confirmed disability accumulation events in 68 (62%) patients: 50 (54%) events related to relapse activity worsening and 43 (46%) PIRA events, including 17 (18%) with MRI activity. The risk of PIRA between two visits (stable event as the reference category) was associated with Expanded Disability Status Scale (EDSS) score (HR: 1.41; 95% CI: 1.18 to 1.69; p<0.001), disease duration (HR: 0.75; 95% CI: 0.62 to 0.90; p<0.005) and new lesions between the visits (HR: 1.09 per lesion; 95% CI: 1.01 to 1.17; p<0.05). As compared with PIRA events with MRI activity, PIRA events without such activity occurred in patients with more disability (mean EDSS score 3, p<0.05), longer disease duration (mean 11 years, p<0.001) and greater number of T2-weighted lesions (p<0.05). Conclusion: This study evidenced that inflammatory activity increases the risk of PIRA in early RMS, arguing that a significant part of PIRA is accessible to treatment targeting inflammation in these patients.

---

Fichiers liés : JNNP_2024.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/05/2024
• Auteurs : Jean‐charles VauthierCharlie TouzeBenoit MauvieuxCorentin HingrandPierre‐louis DelaunayStéphane BesnardRomain JouffroyPhilippe NoirezPatrice MaboudouCassandra ParentElsa HeymanMathias Poussel
• Organismes : Département de médecine générale [Univ. Lorraine] Laboratoire de psychologie de l'interaction et des relations intersubjectives Department of General Practice, Maison de Santé des Trois Monts, Dommartin-les-Remiremont, France Department of General Practice, Maison de Santé des Trois Monts, Dommartin-les-Remiremont, France Vertige Extrême Vertige Extrême Vertige Extrême Vertige Extrême Service d'Oto-Rhino-Laryngologie (O.R.L.) et de Chirurgie Cervico-Faciale [CHU Caen] Hôpital Ambroise Paré [AP-HP] Institut de recherche biomédicale et d’épidémiologie du sport Centre de recherche en épidémiologie et santé des populations Performance, Santé, Métrologie, Société - EA 7507 Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488 Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - ULR 7369 - ULR 4488
• Publié dans Physiological Reports le 29/10/2020

---

Résumé : Abstract Acute kidneys injuries (AKIs) have been described in marathon and trail running. The currently available data allows assessment of before/after comparisons but does not allow an analysis of what happens during the race. A multidisciplinary assessment protocol was performed during the first trail of Clécy ( Normandy France ) in November 2021. This allowed an initial assay to be carried out, then at the end of each of the 6 loops of 26 km, and finally after 24 h of recovery. The race extends over 156 km in hilly terrain and 6000 m of elevation gain (D+). The level of impairment according to the RIFLE classification was defined for each runner at each assay. Fifty‐five runners were at the start, and the per protocol analysis involved 36 runners (27 men and 9 women, 26 finishers). Fifteen (41.7%) of the riders presented at least one result corresponding to a “RIFLE risk” level. After 24 h of rest, only one runner still had a “RIFLE Risk”. The distance around the marathon seems to be the moment of greatest risk. For the first time, we find an association between this renal risk and the probability of abandonment. Many runners are vulnerable to kidney damage during long‐duration exercise, which is why it's important to limit risk situations, such as the use of potentially toxic drugs or hydration disorders. The consumption of NSAIDs (nonsteroidal anti‐inflammatory drugs) before or during an ultra‐distance race should therefore be prohibited. Attention should be paid to hydration disorders.

---

Fichiers liés : Physiological Reports - 2024 - Vauthier - Increased risk of acute kidney injury in the first part of an ultra‐trail.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 06/05/2024
• Auteurs : Sridath TulaMarie-Pierre Pacaux-LemoineEmmanuelle Grislin-Le StrugeonPaulo SantosAnna Ma-WyattJean-Philippe Diguet
• Organismes : Laboratoire d'Automatique, de Mécanique et d'Informatique industrielles et Humaines - UMR 8201 FrenCh austRalian labOratory for humanS/autonomouS agents teamING Laboratoire d'Automatique, de Mécanique et d'Informatique industrielles et Humaines - UMR 8201 Laboratoire d'Automatique, de Mécanique et d'Informatique industrielles et Humaines - UMR 8201 FrenCh austRalian labOratory for humanS/autonomouS agents teamING FrenCh austRalian labOratory for humanS/autonomouS agents teamING FrenCh austRalian labOratory for humanS/autonomouS agents teamING

---

Résumé : Effective cooperation between human operators and robots is essential for the accomplishment of crucial tasks in tough and dangerous contexts, such as search and rescue operations. While autonomous robots excel at moving through dangerous conditions, human decisions made on the basis of global knowledge and experience, are still required to adapt to unforeseen events. We used a Human-Machine Cooperation model to address this topic. The model proposes the definitions to analyze the Know-How-to-Operate and Know-How-to-Cooperate competencies of the teaming agents, in relation to the different phases of a shared task. On this basis, we designed four cooperation levels for the team with the addition of an intelligent assistant system (IAS) agent. As a proof-of-concept, these levels have been implemented for evaluation purposes in a team composed of one human, one IAS, and two robots. In our study we demonstrated the practical implementation of the proposed cooperation levels within a human-robot team, emphasizing the Intelligent Assistance System (IAS) agent's ability to improve cooperation and task efficiency in hazardous environments.

---

Fichiers liés : TULA_AAMAS_ARMS_2024.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/05/2024
• Auteurs : Emeric BoisteauLaëtitia DahanNicolas WillietKarine Le MalicotJérôme DesraméOlivier BouchéCaroline PetorinDavid MalkaChristine RebischungThomas AparicioCédric LecailleYves RinaldiAnthony TurpinAnne-Laure BignonJean-Baptiste BachetCôme LepageVictoire GrangerJean-Louis LegouxGaël DeplanqueMathieu BaconnierThierry LecomteIsabelle BonnetJean-François SeitzEric FrançoisAstrid LièvreAnna PiguiAnne EscandeDenis PezetMuriel DulucNicolas BarriereIsabelle MoulletFranck AudemarVincent BourgeoisAgnès Vimal-BaguetEmmanuelle NorguetJean-Paul LagasseJean-Christophe DuchmannMarielle GuilletStéphane BerdahRobert SverdlinJulien TaiebStéphane CorbinaisGérard LledoLaurent BedenneMohamed HebbarKarine Bouhier-LeporrierCharles FerteLionel StaudacherLudovic EvesqueStéphane RemyThierry CharloisCatherine Lombard-BohasAziz ZaananCorina CornilaAntoine HollebecquePascal ArtruLaure Dupont KazmaThomas WalterIris DevaureJulie GigoutAnne GuilngarChristophe LocherJoël EzenfisValérie BoigeStéphane CattanCaroline CoufonCamille Sibertin-BlancAnne-Laure VillingPascal BurtinPierre AndrauJérôme MeunierLe FollMichel DucreuxLaurianne PlastarasGilles BreysacherPhilippe BernardAurelie DurandOlivier RomanoDelphine FarnetiMireille SimonMarie TalarminAnne-Claire Dupont GossartSamuel Le SourdFayçal HocineDavid SefriouiFlorence Le RoyRomain DesgrippesAmalia TopolskiFlorence MaryPierre MichelThomas AparicioGérard CavaglioneNabil Baba-HamedPhilippe FollanaIsabelle CuminLaurence Thomas MarquesNathalie BaizeNicolae ArseniiTatiana CebanJean-Louis JouveYann MolinMarc Pracht
• Organismes : Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Oncogenesis, Stress, Signaling Hôpital de la Timone [CHU - APHM] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Physiopathologie des Dyslipidémies (CTM UMR 1231) Hôpital privé Jean Mermoz [Lyon] Hôpital universitaire Robert Debré [Reims] CHU Clermont-Ferrand Dynamique des cellules tumorales Hopital Saint-Louis [AP-HP] Polyclinique Bordeaux Nord Aquitaine Hôpital Européen [Fondation Ambroise Paré - Marseille] Université de Lille Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Centre Hospitalier Régional d'Orléans Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Oncogenesis, Stress, Signaling
• Publié dans Oncologist le 26/10/2020

---

Résumé : Introduction Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy. Patients and Methods We focused on patients who received 12 cycles of FOLFIRINOX (arm A, N = 88) or 8 cycles of FOLFIRINOX followed by LV5FU2 maintenance in controlled patients (arm B, N = 91) from the PRODIGE-35 trial. Prognostic factors and predictors of efficiency were identified by using Cox regression. Median progression-free survival (PFS), overall survival (OS), and time to deterioration of quality of life (TTD-QoL) were evaluated. Results Poor independent prognostic factors were primary tumor in place, age <65 years and the presence of liver metastases for PFS, a baseline neutrophil/lymphocyte ratio (NLR) ≥5 and CA19.9 ≥500 UI/L for OS, independent of the treatment arm. Patients with one metastatic site had a longer PFS in arm A, whereas patients with ≥2 metastatic sites had a longer PFS in arm B. We also identified predictors of OS and TTD-QoL in arm B but these differences were not statistically significant. Conclusion Except for patients with one metastatic site who benefited more from 12 cycles of FOLFIRINOX, a maintenance strategy with LV5FU2 should be widely offered to mPC patients whose survival and QoL are preserved after 4 months of FOLFIRINOX. (ClinicalTrials.gov: NCT02352337).

---

Fichiers liés : oyae079.pdf

---

Source